VANCOUVER, BC – April 19, 2022 –Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a company commercializing a dedicated breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers, announces that as part of its corporate profile awareness strategy it has engaged GRIT Capital to assist in presenting the Company’s value proposition to new age demographics.
GRIT Capital (“GRIT”) offers multi-platform educational stock market-related content to democratize investing knowledge for Gen Z and Millennial audiences and provide them with access to high-quality investment insights and opportunities. Founded by CEO Genevieve Roch-Decter, a former $100M+ portfolio manager, GRIT has nearly 400,000 followers on social media, and over 56,000 subscribers to their complimentary and paid newsletters which has grown 10x over the past 18 months. In addition to newsletters and general social media posts, GRIT has cultivated a following on YouTube using a weekly livestream show where they partner with an investing influencer who has nearly 400,000 followers on TikTok and Benzinga, which is a financial media platform with +25 million readers.
The Company will be sponsoring both GRIT’s newsletter and YouTube live streams and will establish a new landing page specially crafted to tell the Izotropic story in a new way to a new era of investors. To further support awareness on TikTok, the Company will be launching an official brand presence on the platform and will be posting short videos focused on simplifying the Company’s overall value proposition, the capabilities and development of IzoView Breast CT technology, and investment catalysts on the path to commercialization.
“Investors in this age range care greatly about socially responsible investin[2], and with over 40% of Gen Z turning to social media to learn about investing[2] it’s a logical step for Izotropic to develop content for users in this demographic and to further our presence on social media including on TikTok,” said CEO Dr. John McGraw.
To bring awareness to Izotropic’s profile within the modern Gen Z and Millennial investor age demographics, the Company has engaged GRIT for a six-month term under a shares for services agreement in keeping with CSE Policy 6. Under the terms of the agreement, the Company will issue 181,495 common shares, the equivalent of USD $95k in lieu of cash. The common shares are priced at yesterday’s closing price of $0.66 and are subject to a hold period of four months and one day. Awareness coverage will commence the first week of May, 2022.
ON BEHALF OF THE BOARD
Investor Relations Contact:
James Berard
Email: jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1
Media Inquiries Contact:
Jaclyn Thast
Email: jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3
About Izotropic Corporation
Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures and will initiate in Q2 2022. In follow-on clinical studies, Izotropic intends to validate platform applications, including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
Forward-Looking Statements
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView is not yet approved for sale.